{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:56:14Z","timestamp":1792061774178,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.cld.2009.05.009","type":"journal-article","created":{"date-parts":[[2009,7,22]],"date-time":"2009-07-22T09:19:43Z","timestamp":1248254383000},"page":"441-452","source":"Crossref","is-referenced-by-count":14,"title":["Telaprevir: Hope on the Horizon, Getting Closer"],"prefix":"10.1016","volume":"13","author":[{"given":"Ilan S.","family":"Weisberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2009.05.009_bib2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2009.05.009_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"PegInterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2009.05.009_bib4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.21932","article-title":"Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial","volume":"46","author":"Jacobson","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib5","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/S0168-8278(08)60993-9","article-title":"Final results of the IDEAL (individualized dosing efficacy versus flatdosing to assess optimal pegylated interferon therapy) phase IIIB study","volume":"48","author":"Sulkowski","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2009.05.009_bib6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","article-title":"Peginteferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1","volume":"131","author":"Conjeevaram","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2009.05.009_bib7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2009.05.009_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.21670","article-title":"Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genoytpe 1","volume":"46","author":"Jacobson","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cld.2009.05.009_bib10","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1128\/JVI.67.7.3835-3844.1993","article-title":"Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for the cleavage of the NS3\/4 and NS4\/5 junctions","volume":"67","author":"Bartenschlager","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2009.05.009_bib11","first-page":"2046","article-title":"Hepatitis C virus encoded enzymatic activities and conserved elements in the 3' nontranslated region are essential for virus replication in vivo","volume":"74","author":"Kolykhalov","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2009.05.009_bib12","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.1082604","article-title":"Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease","volume":"300","author":"Foy","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.cld.2009.05.009_bib13","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1073\/pnas.0408824102","article-title":"Immune evasion by hepatitis C virus NS3\/4A mediated protease cleavage of the toll like receptor 3 adaptor protein TRIF","volume":"102","author":"Li","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cld.2009.05.009_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.cld.2009.05.009_bib15","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/j.gastro.2004.08.002","article-title":"Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis genotype 1\u00a0patients","volume":"127","author":"Hinrichsen","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2009.05.009_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2009.05.009_bib17","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1128\/AAC.50.5.1813-1822.2006","article-title":"VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells","volume":"50","author":"Lin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2009.05.009_bib18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2009.05.009_bib19","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/AAC.48.12.4784-4792.2004","article-title":"Combination of hepatitis C virus NS3-4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells","volume":"48","author":"Lin","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2009.05.009_bib20","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.M313020200","article-title":"In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061","volume":"279","author":"Lin","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cld.2009.05.009_bib21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.21774","article-title":"Antiviral activity of Telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C","volume":"46","author":"Forestier","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib22","first-page":"819A","article-title":"Final results of patients receiving Peg-Interferon-Alfa-2a (Ped-IFN) and ribavirin (RBV) after a 14-day study of the hepatitis C protease inhibitor telaprevir (VX-950) with Peg-IFN","volume":"S46","author":"Weegink","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhep.2008.03.027","article-title":"Antiviral effects and safety of Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients","volume":"49","author":"Lawitz","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2009.05.009_bib24","first-page":"315A","article-title":"Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-na\u00efve subjects with hepatitis C","volume":"46","author":"Jacobson","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib25","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2009.05.009_bib26","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.cld.2009.05.009_bib27","first-page":"418A","article-title":"Telaprevir in combination with peginterferon alfa-2a with or without ribavirin in the treatment of chronic hepatitis C. Final Results of the PROVE 2 study","volume":"48","author":"Zeuzem","year":"2008","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.cld.2009.05.009_bib28","first-page":"431A","article-title":"A Phase 2b study of telaprevir with peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responder and relapsers following a prior course of peginterferon alfa2a\/b and ribavirin therapy. PROVE 3 interim results","volume":"48","author":"McHutchison","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib29","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2009.05.009_bib30","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1016\/S0168-8278(08)60990-3","article-title":"Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon\/ribavirin (I\/R) nonresponders (NR): Final results from the EPIC3 program","volume":"48","author":"Poynard","year":"2008","journal-title":"J Hepatol"},{"issue":"S1","key":"10.1016\/j.cld.2009.05.009_bib31","first-page":"1135A","article-title":"A study of Telaprevir combined with peginterfeon-alfa-2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon-alfa-2a and ribavirin treatment: Interim analysis","volume":"48","author":"Shiffman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hep.22076","article-title":"Interferon regulatory factor-3 activation, hepatic interferon stimulated gene expression, and immune cell infiltration in hepatitis C virus patients","volume":"47","author":"Lau","year":"2008","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.cld.2009.05.009_bib33","first-page":"1136A","article-title":"Phase 2 study of Telaprevir administered Q8H or Q12H with peginterferon alfa-2a or alfa-2b and ribavirin in treatment na\u00efve patients with genotype 1 hepatitis C: week 12 interim results","volume":"48","author":"Forns","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alpha therapy","volume":"282","author":"Neuman","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.cld.2009.05.009_bib35","doi-asserted-by":"crossref","first-page":"36784","DOI":"10.1074\/jbc.M506462200","article-title":"In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061","volume":"280","author":"Lin","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cld.2009.05.009_bib36","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2009.05.009_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","article-title":"Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients","volume":"46","author":"Kieffer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib38","doi-asserted-by":"crossref","first-page":"22619","DOI":"10.1074\/jbc.M610207200","article-title":"Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg-155 variants","volume":"282","author":"Zhou","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cld.2009.05.009_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.00863-07","article-title":"Phenotypic characterization of resistant Val-36 variants in hepatitis C virus NS3-4A serine protease","volume":"52","author":"Zhou","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2009.05.009_bib40","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/hep.22122","article-title":"Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-na\u00efve chronically infected patient","volume":"47","author":"Colson","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib41","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of HCV resistance variants with decreased sensitivity to NS3-4A protease inhibitors in treatment na\u00efve subjects","volume":"198","author":"Bartels","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cld.2009.05.009_bib42","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-na\u00efve patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.cld.2009.05.009_bib43","first-page":"1131A","article-title":"Viral responses in African-Americans, Latinos, and Caucasians in the US phase 2 study (PROVE1) of telaprevir with peginterferon alfa-2a and ribavirin in treatment na\u00efve genotype 1 infected subjects with hepatitis C","volume":"48","author":"Muir","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib44","unstructured":"Jacobson IM, Everson GT, Gordon SC, et\u00a0al. Telaprevir with peginterferon alfa-2a and ribavirin in treatment-na\u00efve patients with hepatitis C, including African-Americans and those with bridging fibrosis: Subgroup analysis from the phase 2 PROVE 1 trial. 13th Abstract P-113. International Symposium on Viral Hepatitis and Liver Disease, Washington, DC, USA, March 20-24, 2009."},{"key":"10.1016\/j.cld.2009.05.009_bib45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa066403","article-title":"Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3","volume":"357","author":"Shiffman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2009.05.009_bib46","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0168-8278(09)60052-0","article-title":"Activity of telaprevir alone or in combination with peginterferon alpha-2A and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: interim results of study C209","volume":"50","author":"Foster","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.009_bib47","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(09)60012-X","article-title":"Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alpha-2A and ribavirin in treatment-naive genotype 4 HCV patients","volume":"50","author":"Benhamou","year":"2009","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326109000348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326109000348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T22:05:26Z","timestamp":1590012326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326109000348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1089326109000348"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2009.05.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}